Published in Cancer Weekly, July 6th, 2004
Jakob Dupont, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, summarized clinical data from this phase I trial in an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO).These results are part of a clinical development collaboration agreement with Aventis to jointly develop and commercialize the VEGF Trap with Regeneron. The joint development program includes both cancer and eye diseases and budgets...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.